Search Results - "Westerbergh F"

Improving the Somatostatin Receptor Status Assessment for Personalized and Precise Management of Neuroendocrine Neoplasms with the Use of a ^99mTc-Radiolabeled Somatostatin Receptor Antagonist: The Final Results of the ERA PerMed TECANT Clinical Trial

Authors: Hubalewska-Dydejczyk, Alicja Decristoforo, Clemens Mikolajczak, Renata et al.

Source: Journal of Nuclear Medicine. Jun2026, Vol. 67 Issue 6, p895-902. 8p.

¹⁶¹Tb-Based Anti-L1CAM Radioimmunotherapy Shows Superior Efficacy in Eliminating Ovarian Cancer Stem Cells Compared with ¹⁷⁷Lu in Preclinical Models of Ovarian Cancer.

Authors: Todorov, Tihomir Zh. Coelho, Ricardo Dellea, Sharon et al.

Source: Journal of Nuclear Medicine. Jul2026, Vol. 67 Issue 7, p1091-1096. 6p.

Highlight selection of radiochemistry and radiopharmacy developments by editorial board.

Authors: Spreckelmeyer, S. Dasilva, J. Decristoforo, C. et al.

Source: EJNMMI Radiopharmacy & Chemistry. 3/25/2025, Vol. 10 Issue 1, p1-19. 19p.

Quantitative performance of a 3D CZT and conventional SPECT/CT for Tb-161 imaging.

Authors: Nuttens, Victor Imbert, Laetitia Delker, Astrid et al.

Source: EJNMMI Physics. 1/12/2026, Vol. 13 Issue 1, p1-9. 9p.

Alpha Therapy Beyond TOC and TATE—Production, Quality Control, and In-Human Results for the SSTR2 Antagonist DOTA-LM3.

Authors: Greifenstein, Lukas Martin, Marcel Stephan, Sarah et al.

Source: Pharmaceuticals (14248247). Jan2026, Vol. 19 Issue 1, p172. 12p.

Targeted β⁻-Particle Plus Conversion and Auger-Electron Therapy with ¹⁶¹Tb-Labeled Somatostatin Receptor Antagonist DOTA-LM3: A Phase 0 Study.

Authors: Fricke, Julia G. Westerbergh, Frida McDougall, Lisa et al.

Source: Journal of Nuclear Medicine. Mar2026, Vol. 67 Issue 3, p416-422. 7p.

Emerging Theranostic Radiometals (149 Tb, 44 Sc, 52 Mn, 203 Pb, 55 Co)—Decay Diversity, Production Landscape, and Translational Imaging.

Authors: Malik, Noeen Lokesha, Yashas Ullas Habte, Frezghi G. et al.

Source: Pharmaceuticals (14248247). Jun2026, Vol. 19 Issue 6, p889. 34p.

Quantitative terbium-161 SPECT/CT imaging: demonstrating the feasibility of image-based dosimetry and highlighting pitfalls.

Authors: Westerbergh, Frida van der Meulen, Nicholas P. Müller, Cristina et al.

Source: EJNMMI Research. 10/13/2025, Vol. 15 Issue 1, p1-13. 13p.

Potentials and practical challenges of terbium-161 labeled radiopharmaceuticals.

Authors: Ntihabose, Carolline M. Handula, Maryana Piet, Amber et al.

Source: EJNMMI Radiopharmacy & Chemistry. 10/3/2025, Vol. 10 Issue 1, p1-14. 14p.

Peptide Receptor Radionuclide Therapy (PRRT) Using Actinium-225- and Ac-225/Lutetium-177-Labeled (TANDEM) Somatostatin Receptor Antagonist DOTA-LM3 in Patients with Neuroendocrine Neoplasm: A Retrospective Study Concerning Safety and Survival.

Authors: Perrone, Elisabetta Calcagni, Maria Lucia Leccisotti, Lucia et al.

Source: Cancers. Sep2025, Vol. 17 Issue 18, p3070. 16p.

Bridging physics and practice: evaluating sensitivity, septal penetration, and detector dead time in terbium-161 gamma-camera imaging.

Authors: Westerbergh, Frida McDougall, Lisa Ritt, Philipp et al.

Source: EJNMMI Physics. 8/28/2025, Vol. 12 Issue 1, p1-14. 14p.

¹⁶¹Tb-Based Anti-L1CAM Radioimmunotherapy Shows Superior Efficacy in Eliminating Ovarian Cancer Stem Cells Compared with ¹⁷⁷Lu in Preclinical Models of Ovarian Cancer.

Authors: Todorov, Tihomir Zh. Coelho, Ricardo Dellea, Sharon et al.

Source: Journal of Nuclear Medicine. Jul2025, Vol. 66 Issue 7, p1091-1096. 6p.

Production of ¹⁶¹Tb as a promising Auger electron emitter in Iran.

Authors: Vosoughi, Sara Salek, Nafise Samani, Ali Bahrami et al.

Source: Journal of Radioanalytical & Nuclear Chemistry. Dec2024, Vol. 333 Issue 12, p6183-6191. 9p.

Safety and efficacy of [¹⁷⁷Lu]Lu-SibuDAB in patients with progressive metastatic castration-resistant prostate cancer.

Authors: Fernández R Soza-Ried C Kramer V et al.

Source: European journal of nuclear medicine and molecular imaging [Eur J Nucl Med Mol Imaging] 2026 Mar; Vol. 53 (4), pp. 2282-2294. Date of Electronic Publication: 2025 Nov 07.

Publication Type: Journal Article

Journal Info: Publisher: Springer-Verlag Berlin Country of Publication: Germany NLM ID: 101140988 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1619-7089 (Electronic) Linking ISSN: 16197070 NLM ISO Abbreviation: Eur J Nucl Med Mol Imaging Subsets: MEDLINE

Pyridyl-Ala in the third position of radiolabeled somatostatin antagonists: the effect of regioisomeric substitution.

Authors: Mansi, Rosalba Bertarelli, Natalie Del Pozzo, Luigi et al.

Source: EJNMMI Radiopharmacy & Chemistry. 7/1/2025, Vol. 10 Issue 1, p1-18. 18p.

Abstracts.

Source: Journal of Neuroendocrinology. 2025 Supplement, Vol. 37, p1-383. 383p.

Comparison of the tolerability of ¹⁶¹Tb- and ¹⁷⁷Lu-labeled somatostatin analogues in the preclinical setting.

Authors: Busslinger, Sarah D. Mapanao, Ana Katrina Kegler, Kristel et al.

Source: European Journal of Nuclear Medicine & Molecular Imaging. Nov2024, Vol. 51 Issue 13, p4049-4061. 13p.

Challenges in the dose calculation from urine measurements in routine internal monitoring of ¹³¹I and other radionuclides.

Authors: Meisenberg, Oliver Mohsin, Ayesha

Source: Radiation & Environmental Biophysics. Aug2025, Vol. 64 Issue 3, p409-416. 8p.

Subject Terms: *Iodine isotopes, *Radiation dosimetry, *Scientific observation, *Excretion, *Radioisotopes, *Estimation theory, *Standards, Urine collection & preservation

¹⁷⁷Lu-DOTATATE in Combination with PARP Inhibitor Olaparib Is Feasible in Patients with Somatostatin-Positive Tumors: Results from the LuPARP Phase I Trial.

Authors: Hallqvist, Andreas Brynjarsdóttir, Elva Krantz, Tomas et al.

Source: Journal of Nuclear Medicine. May2025, Vol. 66 Issue 5, p707-712. 6p.

EANM'24 Abstract Book Congress Oct 19-23, 2024.

Source: European Journal of Nuclear Medicine & Molecular Imaging. 2024 Suppl 1, Vol. 51, p1-1026. 1026p.